Keyphrases
Urinary Tract Infection
81%
Uropathogenic Escherichia Coli
40%
Bladder
39%
Recurrent Urinary Tract Infections (rUTIs)
38%
Escherichia Coli
36%
Acute Cystitis
27%
Bladder Infection
25%
Uropathogenic E. Coli
19%
Chronic Urinary Tract Infection
19%
FimH
16%
Type 1 pili
14%
Cystitis
13%
Disease Outcome
13%
Murine Model
12%
Acute Urinary Tract Infection
11%
Inflammation
10%
Vaccine Development
10%
Drug Development
10%
Escherichia Coli Infections
9%
Bacterial Virulence
9%
Antibiotics
9%
Urinary Bladder
8%
Urothelial
8%
Cyclooxygenase-2
7%
Mannoside
7%
Mouse Model
7%
Bacterial Infection
7%
Recurrent Infection
7%
Intracellular Bacterial Communities
6%
Innate Immune Response
6%
Host-pathogen Interactions
6%
Mucosal Immunity
6%
Bacterial Cystitis
6%
Host Susceptibility
6%
Adhesin
6%
Lower Urinary Tract
6%
Antibiotic Therapy
5%
Bacterial Strains
5%
Uropathogens
5%
Infectious Diseases
5%
Infected Mice
5%
Inflammatory Response
5%
Hemolysin
5%
HlyA
5%
Enterococcus Faecalis
5%
Pyelonephritis
5%
Multidrug-resistant
5%
Host Response
5%
Caspase-1
5%
Dysregulation
5%
Immunology and Microbiology
Urinary Tract
100%
Uropathogenic Escherichia Coli
51%
Escherichia coli
36%
Pilus
12%
Innate Immune System
10%
Infectious Agent
10%
Immune Response
9%
Bacterial Virulence
9%
Cyclooxygenase
8%
Bladder
8%
Host-Pathogen Interaction
8%
Inflammation Response
7%
Mucosal Immunity
6%
Leukocyte
5%
Dynamics
5%
Bacterial Strain
5%
Host Susceptibility
5%
Hemolysin
5%
Caspase 1
5%
Enterococcus faecalis
5%
Immunity
5%
Pharmacology, Toxicology and Pharmaceutical Science
Urinary Tract Infection
61%
Cystitis
31%
Uropathogenic Escherichia Coli
28%
Infection
19%
Escherichia coli
11%
Escherichia Coli Infection
9%
Vaccine Development
9%
Drug Development
9%
Mannoside
9%
Recurrent Disease
9%
Cyclooxygenase 2
8%
Inflammation
7%
Antibiotics
5%
Antibiotic Therapy
5%